This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exelixis (EXEL) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why the Earnings Surprise Streak Could Continue for Exelixis (EXEL)
by Zacks Equity Research
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Exelixis, Ipsen Receive Positive CHMP Opinion for Cabometyx
by Zacks Equity Research
Exelixis, Inc. (EXEL) and partner Ipsen get a positive opinion from the CHMP for Cabometyx tablets as a monotherapy for the second-line treatment of hepatocellular carcinoma in adults.
Exelixis' Partner Ipsen Gets Approval for Cabometyx in Canada
by Zacks Equity Research
Exelixis (EXEL) and partner Ipsen Biopharmaceuticals Canada gain approval for Cabometyx from Health Canada for the treatment of advanced renal cell carcinoma in adult patients.
Exelixis' Cabometyx Recommended by NCCN for All Types of RCC
by Zacks Equity Research
Exelixis' (EXEL) lead drug, Cabometyx gets updated recommendations from the NCCN.
Exelixis (EXEL) Down 14.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Exelixis (EXEL) Earnings Beat on Strong Cabometyx in Q2
by Zacks Equity Research
Exelixis (EXEL) posts better-than-expected results for the second quarter, propelled by strong demand for Cabometyx. A milestone payment from Ipsen also boosts sales and earnings.
Exelixis (EXEL) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 86.67% and 21.39%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is Exelixis (EXEL) Poised for a Beat Again in Q2?
by Zacks Equity Research
Exelixis (EXEL) is likely to beat earnings again in the second quarter, driven by favourable metrics. Investors will focus on the company's uptake in the first-line RCC setting, along with other updates.
Roche's Tecentriq Gets Breakthrough Therapy Status for HCC
by Zacks Equity Research
The FDA grants breakthrough therapy designation to Roche's (RHHBY) key cancer drug, Tecentriq, in combination with Avastin for the first-line treatment of advanced HCC.
Exelixis (EXEL) Jumps: Stock Rises 8%
by Zacks Equity Research
Exelixis (EXEL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Biotech Stock Roundup: FDA Gives Nod to Amgen's Drugs, EU Approves Exelixis' Cabometyx
by Zacks Equity Research
Label expansion of a few prominent drugs along with pipeline updates were the key areas of focus for investors in the biotech space.
Exelixis' Cabometyx Gets EU Nod for First-Line Kidney Cancer
by Zacks Equity Research
European Commission approves Exelixis' (EXEL) Cabometyx 20 mg, 40 mg and 60 mg for the first-line treatment of adults with intermediate- or poor-risk renal cell carcinoma in the European Union.
Are Options Traders Betting on a Big Move in Exelixis (EXEL) Stock?
by Zacks Equity Research
Investors in Exelixis (EXEL) need to pay close attention to the stock based on moves in the options market lately.
Here's Why You Should Sell Fresenius Medical (FMS) Stock Now
by Zacks Equity Research
A rapidly changing healthcare environment in the United States, sluggish Q1 and competition in the niche markets are major headwinds for Fresenius Medical (FMS).
Radius Health (RDUS) Incurs Narrower-Than-Expected Q1 Loss
by Zacks Equity Research
Radius Health (RDUS) narrower-than-expected loss in the first quarter was encouraging as sales of lead drug Tymlos pick up amid competition.
Exelixis, Applied Optoelectronics and Nvidia as Zacks Bull and Bear of the Day
by Zacks Equity Research
Exelixis, Applied Optoelectronics and Nvidia as Zacks Bull and Bear of the Day
Here's Why You Should Invest in Varian Medical (VAR) Now
by Zacks Equity Research
Strong fundamentals and solid Q2 results make Varian Medical (VAR) a must buy.
Cerner EHR Range Picked by Indiana's FSSA for Patient Care
by Zacks Equity Research
Cerner (CERN) gains as Indiana FSSA chooses its flagship Cerner Millennium solutions to take better care of patients.
Array BioPharma (ARRY) in Focus: Stock Moves 5.5% Higher
by Zacks Equity Research
Array BioPharma (ARRY) was a big mover last session, as the company saw its shares rise more than 5% on the day amid huge volumes.
Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter
by Zacks Equity Research
Zacks.com featured highlights include: Marine Products, Nutrisystem, Exelixis, Illumina and Baxter
Bull of the Day: Exelixis (EXEL)
by Kevin Cook
This profitable biotech is growing at over 50% and just went on sale after a clinical trial failure that analysts weren't even modeling
Trump Announces Plan to Reign In Drug Prices and Pharma Stocks Rally.
by David Borun
Bid U.S. drug makers are seen as largely spared the worst in the Trump Administrations plans to control drug prices.
Hospital Product Sales Drive Mallinckrodt (MNK) Q1 Earnings
by Ekta Bagri
Mallinckrodt's earnings and sales beat in the first quarter boosted investor sentiment as hospital products sales revived.
Valeant (VRX) Rallies on Earnings Beat in Q1, Raises View
by Ekta Bagri
Valeant's (VRX) first-quarter earnings topped estimates driven by growth in Bausch + Lomb/International segment and Salix businesses. The company also upped its view.